As the U.S. stock market experiences a positive streak, with the Dow Jones and S&P 500 extending their gains amidst strong earnings reports and potential tariff adjustments, investors are closely watching how these developments might impact various sectors, including technology. In this dynamic environment, identifying high growth tech stocks often involves looking for companies that demonstrate resilience in adapting to economic shifts and possess innovative capabilities that can leverage current market conditions effectively.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 20.27% | 29.79% | ★★★★★★ |
| Alkami Technology | 20.46% | 85.16% | ★★★★★★ |
| Travere Therapeutics | 28.65% | 66.06% | ★★★★★★ |
| TG Therapeutics | 26.06% | 37.39% | ★★★★★★ |
| Arcutis Biotherapeutics | 26.11% | 58.46% | ★★★★★★ |
| Clene | 62.08% | 64.01% | ★★★★★★ |
| Alnylam Pharmaceuticals | 23.08% | 58.85% | ★★★★★★ |
| AVITA Medical | 27.81% | 55.17% | ★★★★★★ |
| Lumentum Holdings | 21.34% | 120.49% | ★★★★★★ |
| Ascendis Pharma | 32.75% | 59.64% | ★★★★★★ |
Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Halozyme Therapeutics (NasdaqGS:HALO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Halozyme Therapeutics, Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of proprietary enzymes and devices both in the United States and internationally, with a market capitalization of approximately $7.47 billion.
Operations: Halozyme Therapeutics generates revenue primarily from the research, development, and commercialization of its proprietary enzymes, totaling approximately $1.02 billion. The company's focus is on leveraging its enzyme technology for various therapeutic applications across global markets.
Halozyme Therapeutics, a biotech firm, recently announced significant regulatory milestones with its ENHANZE® drug delivery technology. The European Medicines Agency's positive opinion for VYVGART®, developed using this technology, marks a pivotal advancement in treating chronic inflammatory conditions. Financially, Halozyme has shown robust performance with a 57.7% earnings growth over the past year, outpacing the industry's 40.6%. Moreover, their strategic share repurchases have reinforced shareholder value, with $250 million spent to buy back 3.29% of shares last quarter. This blend of innovative healthcare solutions and strong financial health underscores Halozyme's potential in high-growth biotechnology sectors.
Intapp (NasdaqGS:INTA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Intapp, Inc., through its subsidiary Integration Appliance, Inc., offers AI-powered solutions across the United States, the United Kingdom, and internationally with a market cap of approximately $4.32 billion.
Operations: Intapp generates revenue primarily from its Software & Programming segment, reporting $465.03 million in this area. The company's operations focus on delivering AI-powered solutions globally, leveraging technology to enhance business processes.
Intapp's recent unveiling of the AI-driven DealCloud Activator at its annual product event showcases a strategic pivot towards enhancing business development through technology. This platform, underpinned by behavioral science, aims to optimize client lifecycle management and has been integrated with essential tools like email and LinkedIn for seamless operation. Financially, Intapp reported a revenue increase to $121.21 million in Q2 2025 from $103.93 million the previous year, although it still operates at a loss with a net loss of $10.22 million in the same quarter. These moves highlight Intapp’s commitment to innovation despite financial challenges, positioning it uniquely within tech circles for potential future growth as it continues expanding its R&D efforts globally, including a new hub in Lisbon aimed at bolstering its AI capabilities.
- Click here and access our complete health analysis report to understand the dynamics of Intapp.
Explore historical data to track Intapp's performance over time in our Past section.
Workiva (NYSE:WK)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Workiva Inc. offers cloud-based reporting solutions across the Americas and internationally, with a market capitalization of approximately $4.10 billion.
Operations: Workiva generates revenue primarily through its data processing segment, which accounted for $738.68 million. The company focuses on cloud-based solutions for reporting needs across various regions.
Amidst a transformative phase, Workiva has demonstrated robust financial and operational agility. With an impressive 13.7% annual revenue growth, the company outpaces the U.S. market's average of 8.2%. This growth trajectory is accompanied by a forecasted earnings surge of approximately 74.73% annually, signaling potential profitability within three years—a stark improvement from its current unprofitable status. Notably, Workiva’s commitment to innovation is evident in its R&D investments, crucial for sustaining its competitive edge in the rapidly evolving tech landscape. Recent strategic activities include proposing amendments to enhance governance structures and engaging prominently at industry conferences, further positioning it as a forward-thinking player in tech circles.
- Delve into the full analysis health report here for a deeper understanding of Workiva.
Assess Workiva's past performance with our detailed historical performance reports.
Next Steps
- Discover the full array of 233 US High Growth Tech and AI Stocks right here.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Halozyme Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com